Mark McDade co-founded Qiming Venture Partners USA in January 2017 and has over 30 years of successful operating experience in private and public healthcare and life sciences companies. Prior to Qiming, Mark was Executive Vice President and ChiefOperating Officer (COO) of UCB, the Brussels, Belgium-based global biopharma.
Previously, Mark served as ChiefExecutive Officer (CEO) and a director of PDL Biopharma and led SignatureBioscience as its CEO. Mark also was a founder and director of Corixa Corporation, where he served as COO and then as President & COO. Earlier in his career, Mark was COO of Boehringer Mannheim Therapeutics, the biopharmaceutical division of Corange. Prior to that, he held several positions of increasing responsibility at Sandoz Ltd. (now Novartis), including business development, product management, and general management.
Mark is on the boards of several of Qiming’s portfolio companies, notably serving as chairman of the board of Icosavax (Nasdaq: ICVX). He previously served as chairman of the board of Aimmune Therapeutics until its acquisition by NestléHealth Sciences and as a director of Dermira until its acquisition by Eli Lilly& Company. He also serves as a director of Mumbai-based Lupin Ltd. and as a trustee of the National MarineSanctuary Foundation.
Mark received a B.A. from Dartmouth College and an M.B.A. from the Harvard Business School.
